Login / Signup

Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.

Jiangping YangJiaqi HanNi ZengXi Yan
Published in: Therapeutic advances in medical oncology (2023)
T-DXd provides significant health benefit for patients with HER2-low mBC compared with chemotherapy but is unlikely to be cost-effective in the United States.
Keyphrases